Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: A cautionary tale

PLoS ONE

Volumn 4, Issue 5, 2009, Pages

  Mintzes, Barbara ^a   Morgan, Steve ^a   Wright, James M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ATORVASTATIN; BOTULINUM TOXIN A; CELECOXIB; DIANE; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORGESTIMATE; ISOTRETINOIN; PAROXETINE; SILDENAFIL; TADALAFIL; TRICYCLEN LO; UNCLASSIFIED DRUG; VALACICLOVIR; VARDENAFIL; PRESCRIPTION DRUG;

ARTICLE; CANADA; CONTROLLED STUDY; DRUG CONTROL; DRUG LEGISLATION; DRUG MARKETING; DRUG SAFETY; TELECOMMUNICATION; TELEVISION; UNITED STATES; ADVERTIZING; CONSUMER; DRUG TOXICITY; ECONOMIC ASPECT; ECONOMICS; FINANCIAL MANAGEMENT; HUMAN; MASS MEDIUM;

ADVERTISING AS TOPIC; CANADA; CONSUMER PARTICIPATION; DRUG TOXICITY; HUMANS; INFLATION, ECONOMIC; LEGISLATION, DRUG; MARKETING OF HEALTH SERVICES; MASS MEDIA; PRESCRIPTION DRUGS; UNITED STATES;

EID: 66349131115     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005699     Document Type: Article

References (36)

1. Law M, Majumdar SR, Soumerai SB (2008) Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada. BMJ 337: a1055.
2. Merck Frosst (1996) Direct-to-Consumer Advertising of Prescription Pharmaceuticals. A Merck Frosst Position Paper on How to Use Comprehensive Patient Information to Deliver Improved, Cost-Effective Health Outcomes. Submission to Health Canada Consultation on Direct-to-Consumer Advertising of Prescription Drugs. Ottawa: June 17, 1996.
3. Nichols DM (2005 Aug) The Distinction Between Advertising and Other Activities. Administrative update of January 12, 1996 policy. Health Products and Food Branch, Health Canada. Available: http://www.hc-sc.gc.ca/dhp-mps/advert-publicit/pol/ actv_promo_vs_info-eng.php via the Internet. Accessed 03 March 2009.
4. Gardner DM, Mintzes B, Ostry A (2003) Direct-to-consumer prescription drug advertising in Canada: Permission by default? CMAJ 169: 425-427.
5. Woodcock J (2003) Director, Center for Drug Evaluation and Research. US Food and Drug Administration. FDA Regulates prescription drug promotion. Testimony before the Senate Special Committee on Aging. July 22, 2003. Washington DC. Accessed November 17, 2008. Available: http://www.fda.gov/ ola/2003/AdvertisingofPrescriptionDrugs0722.html via the Internet. Accessed 03 March 2009.
6. Rowsell LB (2000) Advertising Campaigns of Branded and Unbranded Messages. Policy statement. Therapeutic Products Directorate, Health Canada, November 2000.
7. Canada's Food and Drugs Act and Regulations. Available: www.hc-sc.gc.ca/food-aliment/friia-raaii/ food_drugsaliments_drogues/act-loi/e_index.html via the Internet. Accessed 03 March 2009.
8. Sztuke-Fournier A (2006) Ontario Superior Court of Justice. Between CanWest MediaWorks Inc. and Attorney General of Canada. Affidavit of Ann Sztuke-Fournier. 05-CV-303001PD2. June 2006. Available: http://www.whp-apsf.ca/en/documents/charter.html via the Internet. Accessed 04 May 2009.
9. Rosenthal MB, Berndt ER, Donohue JM, Epstein AM, Frank RG (2002) Promotion of prescription drugs to consumers. N Engl J Med 346: 498-505.
10. Donohue JM, Cevasco M, Rosenthal MB (2007) A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med 357: 673-81.
11. IMS Health (2008) Total US Promotional Spend by Type, 2007. Available: www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/ Top_Line_Data/PromotionalSpendChartWebsite.pdf via the Internet. Accessed 03 March 2009.
12. Health Canada. Health Canada advises about vision problems possibly associated with Viagra, Cialis and Levitra. Advisory. July 26, 2005. Available: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2005/ 2005_83-eng. php via the Internet. Accessed 03 March 2009.
13. Marketed Health Products Directorate, Health Canada (2002) Important Safety Concerns on the Use of Diane-35. December 19, 2002. Available: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2002/ diane-35_hpc-cpseng.php via the Internet. Accessed 03 March 2009.
14. Health Canada (2003) Public Advisory: Diane-35 and the risk of venous thromboembolism. Berlex Canada Inc. Consumer Information. Available: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/_2003/ diane-35_pa-ap-eng.php via the Internet. Accessed 03 March 2009.
15. Cotter J, Wooltorton E (2005) New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra). CMAJ 172(10): 1299.
16. Health Canada (2002) Important safety information for patients taking Celebrex. Advisory May 23, 2002. Ottawa. Available: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2002/ 2002_40-eng.php via the Internet. Accessed 03 March 2009.
17. Health Canada (2004) Updated safety information on increased cardiovascular risk with Celebrex (celecoxib). December 17, 2004. Ottawa. Available: http:// www.hc-sc.gc.ca/ahc-asc/media/ advisories-avis/_2004/2004_67-eng.php via the Internet. Accessed 03 March 2009.
18. Health Canada (2005) Health Canada has asked Pfizer to suspend sales of its drug Bextra™ and informs Canadians of new restrictions on the use of Celebrex. April 7, 2005. Available: http://www.hc-sc.gc.ca/ ahc-asc/media/advisories-avis/_2005/2005_17-eng.php via the Internet. Accessed 03 March 2009.
19. US Food and Drug Administration (2005) FDA Updates Labeling for Ortho Evra Contraceptive Patch. November 2005. Available: http://www.fda.gov/ bbs/topics/news/2005/NEW01262.html via the Internet. Accessed 03 March 2009.
20. Mintzes B, Morgan S, Bassett KL (2005) Medicine by media: did a critical television documentary affect prescribing of cyproterone - estradiol (Diane 35). CMAJ 173: 1313-1315.
21. Topol EJ (2004) Failing the Public Health - Rofecoxib, Merck, and the FDA. N Engl J Med 351: 1707-1709.
22. PhRMA (2005) Guiding Principles. Direct-to-consumer advertisements about prescription medicines. August 2005. Available: http://www.phrma.org/ files/DTCGuidingprinciples.pdf via the Internet. Accessed 04 May 2009.
23. Anon (2005) FDA, PhRMA set to make major DTC announcements. Medical Marketing & Media. August 2, 2005.
24. Frosch DL, Krueger PM, Hornik RC, Cronholm PF, Barg FK (2007) Creating Demand for Prescription Drugs: A Content Analysis of Television Direct-to- Consumer Advertising. Ann Fam Med 5: 6-13.
25. Brownfield ED, Bernhardt JM, Phan JL, Williams MV, Parker RM (2004) Direct-to-Consumer Drug Advertisements on Network Television: An Exploration of Quantity, Frequency, and Placement. Journal of Health Communication 9: 491-497.
26. Stupak B (2008) "Direct-to-consumer advertising. Marketing, education or deception?" Chairman's Opening Statement. Subcommmittee on oversight and investigations. House Committee on Energy and Commerce, US Congress. Washington DC: May 8, 2008. Available: http://energycommerce.house.gov/Subcommittees/OI-Stupak/ 050808.OI.hrg.DTC.pdf. Accessed March 23, 2009.
27. FDA Alert (2007) Information for healthcare professionals: erythropoiesis stimulating agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]. Rockville, MD: Food and Drug Administation, March 9, 2007. Available: http://www.fda.gov/cder/ drug/InfoSheets/HCP/RHE2007HCP.htm via the Internet. Accessed 03 March 2009.
28. US Government Accountability Office (2006) Prescription drugs: improvements needed in FDA's oversight of direct-to-consumer advertising. Washington DC. GAO-07-54. November 2006. Available: www.gao.gov/cgi-bin/getrpt?GAO- 07-54 via the Internet. Accessed 03 March 2009.
29. Kaphingst KA, Rudd RE, Dejong W, Daltroy NL (2005) Comprehension of information in three direct-to-consumer television prescription drug advertisements among adults with limited literacy. Journal of Health Communication 10: 609-619.
30. Kallen A, Woloshin S, Shu J, Julh E, Schwartz L (2007) Direct-to-consumer advertisements for HIV antiretroviral medications: a progress report. Health Affairs 26: 1392-1398.
31. Bell RA, Wilkes MS, Kravitz RL (2000) The educational value of consumer-targeted prescription drug print advertising. J Fam Pract 49(12): 1092-1098.
32. Woloshin S, Schwartz LM, Tremmel J, Welch HG (2001) Direct-to-consumer advertisements for prescription drugs: What are Americans being sold? Lancet 358: 1141-1146.
33. Mintzes B, Barer ML, Kravitz RL, Bassett K, Lexchin J, et al. (2003) How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. CMAJ 169: 405-412.
34. Standing Committee on Health (2004 April) Opening the Medicine Cabinet: First Report on Health Aspects of Prescription Drugs. Ottawa: House of Commons. Available: www.parl.gc.ca/InfocomDoc/Documents/37/3/parlbus/ commbus/house/reports/healrp01/healrp01-e.pdf via the Internet. Accessed 03 March 2009.
35. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, et al. (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet 365(9458): 475-481.
36. Institute of Medicine of the National Academies (2006) The future of drug safety: promoting and protecting the health of the public. Available: http://fermat.nap.edu/books/0309103045/html/15.html via the Internet. Accessed Nov 9 2006.